» Articles » PMID: 17878401

Accelerated Atherogenesis and Neointima Formation in Heparin Cofactor II Deficient Mice

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2007 Sep 20
PMID 17878401
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Heparin cofactor II (HCII) is a plasma protein that inhibits thrombin when bound to dermatan sulfate or heparin. HCII-deficient mice are viable and fertile but rapidly develop thrombosis of the carotid artery after endothelial injury. We now report the effects of HCII deficiency on atherogenesis and neointima formation. HCII-null or wild-type mice, both on an apolipoprotein E-null background, were fed an atherogenic diet for 12 weeks. HCII-null mice developed plaque areas in the aortic arch approximately 64% larger than wild-type mice despite having similar plasma lipid and glucose levels. Neointima formation was induced by mechanical dilation of the common carotid artery. Thrombin activity, determined by hirudin binding or chromogenic substrate hydrolysis within 1 hour after injury, was higher in the arterial walls of HCII-null mice than in wild-type mice. After 3 weeks, the median neointimal area was 2- to 3-fold greater in HCII-null than in wild-type mice. Dermatan sulfate administered intravenously within 48 hours after injury inhibited neointima formation in wild-type mice but had no effect in HCII-null mice. Heparin did not inhibit neointima formation. We conclude that HCII deficiency promotes atherogenesis and neointima formation and that treatment with dermatan sulfate reduces neointima formation in an HCII-dependent manner.

Citing Articles

Thrombin-activated interleukin-1α drives atherogenesis, but also promotes vascular smooth muscle cell proliferation and collagen production.

Burzynski L, Morales-Maldonado A, Rodgers A, Kitt L, Humphry M, Figg N Cardiovasc Res. 2023; 119(12):2179-2189.

PMID: 37309666 PMC: 10578913. DOI: 10.1093/cvr/cvad091.


HDL-Associated Proteins in Subjects with Polycystic Ovary Syndrome: A Proteomic Study.

Butler A, Moin A, Reiner Z, Sathyapalan T, Jamialahmadi T, Sahebkar A Cells. 2023; 12(6).

PMID: 36980195 PMC: 10047209. DOI: 10.3390/cells12060855.


Globefish-Inspired Balloon Catheter with Intelligent Microneedle Coating for Endovascular Drug Delivery.

Zhang X, Cheng Y, Liu R, Zhao Y Adv Sci (Weinh). 2022; 9(34):e2204497.

PMID: 36257827 PMC: 9731713. DOI: 10.1002/advs.202204497.


Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.

Hara T, Uemoto R, Sekine A, Mitsui Y, Masuda S, Yamagami H J Atheroscler Thromb. 2022; 30(8):871-883.

PMID: 36244745 PMC: 10406648. DOI: 10.5551/jat.63752.


Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.

Grover S, Mackman N Front Cardiovasc Med. 2022; 9:878199.

PMID: 35592395 PMC: 9110684. DOI: 10.3389/fcvm.2022.878199.


References
1.
Cheung W, Dandrea M, Andrade-Gordon P, Damiano B . Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 1999; 19(12):3014-24. DOI: 10.1161/01.atv.19.12.3014. View

2.
McGuire E, Tollefsen D . Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem. 1987; 262(1):169-75. View

3.
Shirk R, Parthasarathy N, San Antonio J, Church F, Wagner W . Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem. 2000; 275(24):18085-92. DOI: 10.1074/jbc.M001659200. View

4.
Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M . Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest. 2000; 106(7):873-8. PMC: 517819. DOI: 10.1172/JCI10489. View

5.
Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F . PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest. 2001; 107(8):1025-34. PMC: 199556. DOI: 10.1172/JCI11497. View